EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates

Saket Agarwal iD, Elizabeth Taft, Micah Gauthier, Justin Darcy, Kira Buckowing, Daniel Berman, Wendell P Davis, Arlin B Rogers, Maja M Janas

Nucleic Acid Therapeutics · 01.06.2025 · 35 (3) · 125-136

DOI: 10.1089/nat.2024.0090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 05.06.2025. Verfasst von Saket Agarwal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Acetylgalactosamine, RNA, Small Interfering, Argonaute Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonclinical safety screening of small interfering RNAs (siRNAs) conjugated to a trivalent N -acetylgalactosamine (GalNAc) ligand is typically carried out in rats at exaggerated exposures in a repeat-dose regimen. We have previously shown that at these suprapharmacological doses, hepatotoxicity observed with a subset of GalNAc–siRNAs is largely driven by undesired RNA-induced silencing complex (RISC)-mediated antisense strand seed-based off-target activity, similar to microRNA-like regulation. However, the RISC component requirements for off-target activity of siRNAs have not been evaluated. Here, we evaluate the roles of major RISC components, AGO and TNRC6 (or GW182) proteins, in driving on- and off-target activity of GalNAc–siRNAs in hepatocytes, in vitro and in vivo . We demonstrate that knocking down AGO2, but not AGO1 or AGO4, is protective against GalNAc–siRNA-driven off-target activity and hepatotoxicity. As expected, knocking down AGO2, but not AGO1 or AGO4, reduces the on-target activity of GalNAc–siRNA. Similarly, knocking down TNRC6 paralogs, TNRC6A or TNRC6B, but not TNRC6C, is protective against off-target activity and hepatotoxicity while having minimal impact on the on-target activity of GalNAc–siRNA. These data indicate that while AGO2 is the only RISC component required for the on-target activity of GalNAc–siRNAs, the undesired off-target activity and hepatotoxicity of a subset of GalNAc–siRNAs are mediated via the RISC composed predominantly of AGO2 and TNRC6 paralogs TNRC6A and/or TNRC6B.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetylgalactosamineRNA, Small InterferingArgonaute ProteinsAnimalsHumansHepatocytesAutoantigensRNA-Induced Silencing ComplexRatsMiceRNA-Binding ProteinsMaleLiver

Stichwörter der Autor:innen

AGOGW182RNAiTNRC6siRNA

Substanzen

AcetylgalactosamineRNA, Small InterferingArgonaute ProteinsAutoantigensRNA-Induced Silencing ComplexTNRC6A protein, humanRNA-Binding ProteinsAGO2 protein, human

Autor:innen und Institutionen

  • Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.

ORCID-Profile: Saket Agarwal

Zitieren

APA

Agarwal, S., Taft, E., Gauthier, M., Darcy, J., Buckowing, K., Berman, D., Davis, W. P., Rogers, A. B., & Janas, M. M. (2025). Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates. Nucleic Acid Therapeutics, 35(3), 125-136. https://doi.org/10.1089/nat.2024.0090

Vancouver

Agarwal S, Taft E, Gauthier M, Darcy J, Buckowing K, Berman D, et al. Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates. Nucleic Acid Therapeutics. 2025;35(3):125-136. doi:10.1089/nat.2024.0090

BibTeX
@article{Agarwal2025,
  author = {Agarwal, Saket and Taft, Elizabeth and Gauthier, Micah and Darcy, Justin and Buckowing, Kira and Berman, Daniel and Davis, Wendell P and Rogers, Arlin B and Janas, Maja M},
  title = {Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates},
  journal = {Nucleic Acid Therapeutics},
  year = {2025},
  volume = {35},
  number = {3},
  pages = {125--136},
  doi = {10.1089/nat.2024.0090}
}
Kostenlos starten →